Wave Life Sciences Ltd. (WVE) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001631574

P/B 24.94

P/E -25.48

P/S 28.44

Market Cap 3.11 Bn

ROIC (Qtr) -89.06

Div Yield % 0.00

Rev 1y % (Qtr) 199.11

Total Debt (Qtr) 19.77 Mn

Debt/Equity (Qtr) 0.16

About

Healthy cash reserves of 196.22M provide 23.38x coverage of short-term debt 8.39M, demonstrating strong liquidity position and minimal refinancing risk.
Strong tangible asset base of 241.38M provides 12.21x coverage of total debt 19.77M, indicating robust asset backing and low credit risk.
Operating cash flow of (197.37M) fully covers other non-current liabilities (46.52M) by 4.24x, showing strong long-term stability.
Strong cash position of 196.22M provides 3.11x coverage of other current liabilities 63.01M, indicating excellent liquidity.
Cash reserves of 196.22M provide robust 2.28x coverage of current liabilities 85.90M, indicating strong short-term solvency.

Investment activities of (805000) provide weak support for R&D spending of 174.61M, which is -0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
Operating cash flow of (197.37M) provides insufficient coverage of deferred revenue obligations of 58.21M, which is -3.39x, raising concerns about future service delivery capabilities.
The company's operating cash flow of (197.37M) shows concerning coverage of stock compensation expenses of 20.86M, with a -9.46 ratio indicating potential earnings quality issues.
Free cash flow of (198.17M) provides weak coverage of capital expenditures of 805000, with a -246.17 ratio suggesting additional external financing needs for growth initiatives.
Operating earnings of (121.95M) show weak coverage of depreciation charges of 8.75M, with a -13.94 ratio indicating high capital intensity and potential reinvestment needs.

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,349.40 Bn	-1,464.17	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	437.43 Bn	6,381.20	87.97	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	116.09 Bn	31.59	9.90	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	78.10 Bn	17.06	5.48	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	55.87 Bn	1,282.42	17.40	3.21 Bn
6	ARGX	Argenx Se	52.85 Bn	35.08	27,559.65	-
7	BNTC	Benitec Biopharma Inc.	41.75 Bn	-998.33	0.00	0.00 Bn
8	INSM	INSMED Inc	37.80 Bn	-31.93	84.56	0.74 Bn

Metric	Value	Industry
EV to Assets	12.10	12.31
EV to Cash from Ops.	-14.80	23.25
EV to Debt	147.69	738.44
EV to EBIT	-23.95	-9.16
EV to EBITDA	-22.96	6.95
EV to Free Cash Flow [EV/FCF]	-14.74	21.90
EV to Market Cap	0.94	65.67
EV to Revenue	26.73	227.32
Price to Book Value [P/B]	24.94	22.34
Price to Earnings [P/E]	-25.48	-11.77

Metric	Value	Industry	Percentile
Dividend Coverage Ratio	0.00	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	0.00	841.00

Metric	Value	Industry
Capex Growth (1y) %	33.36	-27.13
Cash and Equivalents Growth (1y) %	-36.90	734.65
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	14.43	-46.93
EBITDA Growth (1y) %	11.27	-1.68
EBIT Growth (1y) %	14.43	-56.45
EBT Growth (1y) %	14.43	-12.70
EPS Growth (1y) %	41.44	-28.31
FCF Growth (1y) %	-39.73	-31.90
Gross Profit Growth (1y) %	103.75	226.84

Metric	Value	Industry
Asset Utilization Ratio	0.45	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	2.28	3.85
Current Ratio	2.51	7.27
Debt to Equity Ratio	0.16	0.40
Interest Cover Ratio	0.00	841.00
Times Interest Earned	0.00	841.00

Metric	Value	Industry
EBITDA Margin %	-103.60	-18,234.31
EBIT Margin %	-111.64	-18,580.80
EBT Margin %	-111.64	-19,488.74
Gross Margin %	100.00	-7.59
Net Profit Margin %	-111.60	-19,439.22